Last updated on September 2018

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Gu rin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Brief description of study

The purpose of this study is to test if an experimental drug called Durvalumab (Medi4736) given by intravenous (IV) infusion is effective in treating carcinoma in situ (CIS) of the bladder that no longer responds to Bacillus Calmette-Gurin (BCG) and to collect information on the safety of these drugs and whether they cause any side effects.

Clinical Study Identifier: NCT02901548

Contact Investigators or Research Sites near you

Start Over

Wade Sexton, M.D.

H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL United States
  Connect »